RecruitingPhase 1Phase 2NCT04046900

Vaginal Microbiota Transplant

Vaginal Microbiota Transplant to Promote Lactobacillus-dominant Cervicovaginal Communities

Sponsor

Douglas Kwon

Enrollment

62 participants

Start Date

Apr 22, 2021

Study Type

INTERVENTIONAL

Conditions

Recurrent Bacterial Vaginosis

Summary

This is a randomized trial of vaginal microbiome transplant vs. saline placebo to restore a Lactobacillus dominant vaginal microbial community in women with recurrent bacterial vaginosis.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Oral Metronidazole, Sterile saline, and others for people with recurrent bacterial vaginosis. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years to 50 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALVaginal microbiome transplant

Vaginal fluid from healthy donors

DRUGOral Metronidazole

500mg oral metronidazole twice daily for 7 days

OTHERSterile saline

700 uL of sterile saline placed in the vagina as a placebo intervention.

Locations(1)

Massachusetts General Hospital

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04046900

Related Trials

Evaluation of the Medical Device Vagitab - T as Adjuvant Therapy in Patients With Bacterial Vaginosis.

NCT067258881 location